Statera Biopharma, Inc. STAB
Set alert
At close · Oct 30
- YTD
- -66.67%
- 1 year
- 0.00%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 7.14K
- Vol
- 700
- Avg vol
- 25.02K
- EPS
- -0.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.39
- Inst. own
- 5.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 1, 2024
- 50-d avg
- 0.076158
- 200-d avg
- 0.168793
- 1y target
- 0.00
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| RSI: Overbought | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 1.64M
- Enterprise value
- 9.10M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.44
- Price / book
- 0.00
- EPS (TTM)
- -0.762
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.69M
- Revenue growth
- 183.50%
- Free cash flow
- 340.10K
- Total cash
- 506.10K
- Total debt
- 7.41M
- Return on equity
- -286.94%
- Shares outstanding
- 54.66M
- Short % of float
- 1.65%
- 50-day average
- 0.076158
- 200-day average
- 0.168793
Analyst view
Consensus: none
Next earnings
Jan 1, 2024
Expected Jan 1, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 1, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | -0.07 | — | — |
| Nov 15, 2021 | Sep 1, 2021 | 0.00 | -0.47 | — | — |
About Statera Biopharma, Inc.
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- staterabiopharma.com
News
- CLARIANE BNP Paribas Primary New Issues: NO STAB Notice
- NEOPHARMED - BNP Paribas Primary New Issues: NO STAB Notice
- BNP Paribas Primary New Issues: STAB Notice
- BNP Paribas Primary New Issues: STAB Notice - BioGroup
- BNP Paribas Primary New Issues: No STAB Notice - HOMEVI
- BNP Paribas Primary New Issues: No STAB Notice - Lutech
- BNP Paribas Primary New Issues: Post-STAB Notice - No Stab NEW IMMO HOLDING
- CLARIANE BNP Paribas Primary New Issues: NO STAB Notice
- AZELIS - BNP Paribas Primary New Issues: NO STAB Notice
- BNP Paribas Primary New Issues: POST STAB NOTICE - NO STAB - EUTELSAT COMMUNICATIONS
Your note
Sign in to keep a note on STAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARONSTAM PETER | Chief Financial Officer | Stock Award(Grant) | Jul 26, 2021 | 141,370 |
| BARBARICK STEVE K | Director | Stock Award(Grant) | Sep 8, 2021 | 60,000 |
| BUCKHEIT ROBERT | Chief Technology Officer | Stock Award(Grant) | Jul 26, 2021 | 24,378 |
| HANDLEY MICHAEL K | Chief Executive Officer | Stock Award(Grant) | Jul 26, 2021 | 296,609 |
| MARKVICKA TAUNIA | Chief Operating Officer | Stock Award(Grant) | Sep 27, 2021 | 100,000 |
| MCAVOY COZETTE M | Officer | Stock Award(Grant) | Jul 26, 2021 | 60,947 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 2.48% | 1,356,946 | 40.71K | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 0.69% | 378,677 | 11.36K | Sep 29, 2022 |
| Northern Trust Corporation | 0.31% | 171,110 | 5.13K | Sep 29, 2022 |
| Geode Capital Management, LLC | 0.24% | 130,774 | 3.92K | Sep 29, 2022 |
| Blackrock Inc. | 0.20% | 111,751 | 3.35K | Sep 29, 2022 |
| Virtu Financial LLC | 0.19% | 102,385 | 3.07K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.69% | 378,677 | 11.36K | Sep 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.20% | 108,153 | 3.24K | Dec 30, 2022 |
| SunAmerica Series Trust-SA T. Rowe Price Asset Allocation Growth Port | 0.11% | 61,200 | 1.83K | Oct 30, 2022 |
| Fidelity Extended Market Index Fund | 0.10% | 54,957 | 1.65K | Nov 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.05% | 26,219 | 786 | Nov 29, 2022 |
| Fidelity Total Market Index Fund | 0.04% | 22,064 | 661 | Nov 29, 2022 |